title: Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment.
abstract: OBJECTIVE
  We analyzed the clinical outcome of treatment with the expandable metallic stent (EMS) for the superior vena cava (SVC) syndrome associated with malignant tumors, and the results were compared with those of radiotherapy.
  
  
  METHODS
  Of 33 patients with the SVC syndrome, 23 were treated by Gianturco EMS placement and 10 were treated by radiotherapy and/or chemotherapy alone. Of the 23 EMS patients, 11 had treatment before EMS placement and 12 had no treatment before EMS placement.
  
  
  RESULTS
  After stenting, the clinical symptoms disappeared in 78% (18/23) of the patients, i.e. in 50% of the patients with intraluminal tumors, and in 93% of those with extrinsic compression. The clinical symptoms improved in 80% of patients who received radiotherapy. The mean duration of survival was 145 days in patients who underwent stenting, and 146 days in those receiving radiotherapy. However, the survival period differed significantly between patients with intraluminal tumors (44.9 days) and those with extrinsic compression (198.6 days). Between patients with previous treatment and those with no previous treatment, there was no significant difference in response rate or in survival period which were 82% versus 75%, and 127 days versus 162 days, respectively.
  
  
  CONCLUSIONS
  The clinical symptoms showed similar improvement in patients receiving EMS placement or radiotherapy. EMS placement was effective in relieving clinical symptoms in patients who had failed to respond to radiotherapy.
authors.affiliation: Department of Radiology, University Hospital of the Ryukyus, Okinawa, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Tanigawa
authors.forename: S
authors.initials: S
authors.lastname: Sawada
authors.forename: K
authors.initials: K
authors.lastname: Mishima
authors.forename: Y
authors.initials: Y
authors.lastname: Okuda
authors.forename: K
authors.initials: K
authors.lastname: Mizukawa
authors.forename: N
authors.initials: N
authors.lastname: Ohmura
authors.forename: T
authors.initials: T
authors.lastname: Toita
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019917:Blood Vessel Prosthesis Implantation; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000401:mortality / Q000628:therapy; D010690:Phlebography; D018714:Radiotherapy, Adjuvant; D015607:Stents; D013479:Superior Vena Cava Syndrome / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents